Immunogenic antigens for vaccination are often created through the production of recombinant proteins using Escherichia coli.1 As a side product,aggregates called inclusion bodies(IBs)are formed,containing largely mis...Immunogenic antigens for vaccination are often created through the production of recombinant proteins using Escherichia coli.1 As a side product,aggregates called inclusion bodies(IBs)are formed,containing largely misfolded forms of the overexpressed recombinant protein.2 The effect of IBs on the immune system and whether they can be used as effective vaccine products remain unknown.The non-native conformation of proteins upon accumulation in IBs abrogates their use as vaccines aimed at generating high-affinity antibodies.3 However,IBs exhibit unique properties,including mechanical and thermal stability due to their intrinsic particulate nature,biocompatibility,high antigenic content,low toxicity and relative resistance to proteases.These characteristics make IBs attractive as an antigenic vaccine formulation for T cell responses to linear epitopes.Whether IBs can trigger adaptive cellular responses initiated via uptake by dendritic cells for presentation to T cells is unknown.展开更多
基金supported by the European Research Council(ERC-339977-Glycotreat)supported by grants from the Dutch Cancer Society(VU2013-5940 and VU2016-10449).
文摘Immunogenic antigens for vaccination are often created through the production of recombinant proteins using Escherichia coli.1 As a side product,aggregates called inclusion bodies(IBs)are formed,containing largely misfolded forms of the overexpressed recombinant protein.2 The effect of IBs on the immune system and whether they can be used as effective vaccine products remain unknown.The non-native conformation of proteins upon accumulation in IBs abrogates their use as vaccines aimed at generating high-affinity antibodies.3 However,IBs exhibit unique properties,including mechanical and thermal stability due to their intrinsic particulate nature,biocompatibility,high antigenic content,low toxicity and relative resistance to proteases.These characteristics make IBs attractive as an antigenic vaccine formulation for T cell responses to linear epitopes.Whether IBs can trigger adaptive cellular responses initiated via uptake by dendritic cells for presentation to T cells is unknown.
